A phase 1 study to evaluate safety, tolerability, pharmacokinetics and brain biodistribution of UCB0599 using PET in healthy volunteers
Latest Information Update: 12 Aug 2021
At a glance
- Drugs Minzasolmin (Primary) ; Minzasolmin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 12 Aug 2021 New trial record
- 22 Jun 2021 Results (n=4) presented at the 7th Congress of the European Academy of Neurology